Antibody Drug Conjugates for Cancer Therapy

More documents

Recommendations

Info

Comparison of anti-tenB2vc-MMAE in human prostate cancer explant modelsAll single IV dose of 5mg/kgTumor volume (mm 3 )1000800600400200900700500300100LuCAP 35v00 10 20 30 40 50DaySingle IV0 10 20 30 40 50Single IVLuCap96.1DayTenB2vcMMAETenB2vcMMAEExpression ranking8007006005004003002001001000800600400200TenB2: 77 > 96.1 > 70 > 35v00 10 20 30 40 50 60Single IV00 10 20 30 40 50 60Single IVLuCap77LuCap70DayDayTenB2vcMMAETenB2vcMMAE
MRP4 (multi drug resistance protein 4)Affymetrix probes covering all known drug resistance efflux transportersProstate cancerProstate normalMRP4MRP4MRP4Prostate <strong>Cancer</strong>LuCAP xenografts96.177 35v 70MRP4IHC w/ Anti-MRP4immunoblot w/ Anti-MRP4
Page 1 and 2: Antibody Drug Conjugates for Cancer
Page 3: Target Screening- Large scale mRNA-
Page 6 and 7: Naked antibodies are likely to be i
Page 9 and 10: How many xenograft models should we
Page 11 and 12: RelativeTenB2 expression in human p
Page 13: Antibodies armed with auristatinsAN
Page 18 and 19: Structure of the MUC16 antigen and
Page 20 and 21: Endothelin B receptor: A target for
Page 22 and 23: Melanocytes and EDNBR staining in n
Page 24 and 25: Increased cell killing in vitro wit
Page 26 and 27: ETBR Expression in Cell Lines versu
Page 28 and 29: Efficacy/SafetyFour ways for armed
Page 30 and 31: Antibody doses are normalized to dr
Page 32 and 33: In Vivo Efficacy is Retained With T
Page 34 and 35: Cumulative toxicity from long-lived
Page 36: • GNE ADC Team- Susan Spencer- Ke

Antibody Drug Conjugates for Cancer Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?